Pfizer (PFE)Rep. Rob Bresnahan (PA08) disclosed a purchase $15K–$50K

$15,001–$50,000

Reported range · official band, not an exact amount

30 days

Disclosure lag

Traded

Feb 25, 2025

Disclosed

Mar 27, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 15, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
2. Jan 24, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
3. Jan 31, 2025FDAFDA drug approval: Paxlovid (Copackaged)
4. Feb 12, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
5. Feb 13, 2025InsiderDirector purchased ~$499K of PFE shares in the open market
6. Feb 13, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
7. Feb 21, 2025FDAFDA drug approval: Xeljanz
8. Feb 21, 2025FDAFDA drug approval: Xeljanz XR
9. Feb 24, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
10. Feb 25, 2025 · this disclosureCongressDisclosed purchase of PFE — reported range $15,001 - $50,000

What came next

1. Feb 26, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
2. Mar 3, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
3. Mar 4, 2025InsiderOfficer sold ~$65K of PFE shares in the open market
4. Mar 10, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
5. Mar 12, 2025FDAFDA drug approval: Mektovi
6. Mar 12, 2025FDAFDA drug approval: Braftovi
7. Mar 31, 2025Congress · 1 personMembers of Congress: 2 sales
8. Apr 8, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
9. Apr 11, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
10. Apr 21, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
11. Apr 23, 2025FDAFDA drug approval: Ibrance
12. Apr 23, 2025FDAFDA drug approval: Ibrance
13. Apr 29, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
14. May 15, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
15. May 28, 2025FDARecall: DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, For Intravenous Use Only, Made in Italy,…
16. May 30, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
17. Jun 12, 2025FDAFDA drug approval: Talzenna
18. Jun 12, 2025FDAFDA drug approval: Talzenna

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Pfizer

For Pfizer, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

Other recent filings by Rep. Rob Bresnahan (PA08)

• House Clerk periodic transaction report at Berkshire Hathaway (BRK.B)Dec 19, 2025
• House Clerk periodic transaction report at Gitlab (GTLB)Jul 8, 2025
• House Clerk periodic transaction report at Amazon (AMZN)Jul 8, 2025
• House Clerk periodic transaction report at AppLovin (APP)Jul 8, 2025
• House Clerk periodic transaction report at Atlassian (TEAM)Jul 8, 2025

The full history of Rep. Rob Bresnahan (PA08) is on the profile page.

How this filing works

• The STOCK Act

Other disclosures at Pfizer

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its PFE page.